HLB Panagene Co., Ltd. (KOSDAQ:046210)

Market Cap	68.07B -20.4%
Revenue (ttm)	14.64B +14.0%
Net Income	-3.62B
EPS	-79.94
Shares Out	45.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	115,336
Open	1,541.00
Previous Close	1,554.00
Day's Range	1,451.00 - 1,553.00
52-Week Range	1,451.00 - 2,940.00
Beta	-0.23
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 20, 2026

About HLB Panagene

HLB Panagene Co., Ltd. manufactures and sells genetic diagnostic products in South Korea and internationally. It offers PANAMutyper, which detects small amount of mutation with high sensitivity and genotypes multiple mutations for oncology liquid biopsy; PNAClamp, a PNA-based PCR clamping that detects and amplifies only the mutated target DNA sequence for oncology tissue biopsy; PANA RealTyper, a PNA probe-based fluorescence melting curve analysis tool that detects mutation and distinguishes multiple SNPs adjacent for infectious diseases; PANA ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1976
• Employees: 82
• Stock Exchange: KOSDAQ
• Ticker Symbol: 046210

Financial Performance

In 2025, HLB Panagene's revenue was 15.05 billion, an increase of 14.04% compared to the previous year's 13.20 billion. Losses were -3.13 billion, 60.8% more than in 2024.